Skip to main content
Equibles

PHAR · Pharming Group N.V. · Webcasts, Transcripts & Audio

Track PHAR — free

Use PHAR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHAR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.13 -0.13 (-1.06%) At close · Oct 29 Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$859.95M
Shares
70.78M
Volume · Oct 29 12.43K Avg daily vol (3M) 25.01K

Pharming Group N.V. Webcasts

Earnings calls, investor updates, investor days and conferences for Pharming Group N.V. (PHAR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-27
Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Pharming Group N.V. (PHAR) September 15, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Pharming Group N.V. (PHAR) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
Positive tone Ruconest resilience vs oral on-demand competitor Joenja/leniolisib commercial growth Geographic expansion and ex-U.S. launch readiness
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Positive tone Joenja commercial growth and patient expansion RUCONEST revenue decline and inventory dynamics Pipeline programs in PIDs, CVID and mitochondrial disease
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Confident tone Joenja growth and APDS franchise International regulatory and reimbursement Financial performance and profitability
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Date not confirmed
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Confident tone Joenja/APDS franchise expansion RUCONEST commercial growth RUCONEST ex-U.S. withdrawal
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Date not confirmed
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Confident tone Joenja (leniolisib) commercialization in APDS RUCONEST growth and market position APDS patient pool expansion via VUS reclassification
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Confident tone Joenja (leniolisib) commercial uptake and catalysts RUCONEST revenue growth and commercial performance G&A cost reduction initiative
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Confident tone Joenja (leniolisib) launch and APDS franchise RUCONEST revenue growth and HAE market position Pipeline expansion into larger indications (APLS, CVID)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
Positive tone Joenja/leniolisib launch and growth RUCONEST commercial performance Financial performance and guidance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Pharming Group N.V. (PHAR) Q2 2024 Earnings Call Transcript
Confident tone Joenja launch momentum RUCONEST performance and growth Pipeline expansion / leniolisib indications
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript
Confident tone Joenja/leniolisib launch in APDS Revenue guidance and quarterly dynamics RUCONEST franchise performance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Pharming Group N.V. (PHAR) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Pharming Group N.V. (PHAR) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Pharming Group N.V. (PHAR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
Pharming Group N.V. (PHAR) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Pharming Group N.V. (PHAR) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
Pharming Group N.V. (PHAR) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
Pharming Group N.V. (PHAR) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1828316 CUSIP 71716E105 13F (30d) 2 filings 2 filers Visit website Investor relations